XOMA (NASDAQ: XOMA) details 2025 royalty cash, buybacks and litigation costs
Rhea-AI Filing Summary
XOMA Royalty Corporation furnished an updated corporate presentation outlining its royalty aggregation business model, portfolio, and preliminary 2025 financial data. The company focuses on acquiring early- to mid‑stage biotech royalty and milestone rights and highlights a diversified portfolio exceeding 100 assets, with more than $140M in milestones received since 2017 and over $2B in potential future milestones.
The presentation’s preliminary 2025 update shows $49–50M in cash received from royalties and milestones and about $133M of cash, cash equivalents and restricted cash as of December 31, 2025. XOMA repurchased and retired 648,048 common shares during 2025 for $16M, with 11,888,489 common shares outstanding as of February 27, 2026. General and administrative expenses for 2025 include roughly $1M tied to ongoing litigation with Janssen Biotech regarding use of XOMA intellectual property, and the company notes that the outcome and any potential recovery are uncertain.
Positive
- None.
Negative
- None.
Insights
Furnished deck shows solid cash, active buybacks, and ongoing litigation costs.
XOMA Royalty presents itself as a biotech royalty aggregator focused on smaller, earlier‑stage transactions across more than 100 assets. The model aims for growing royalty receipts and low operating expenses to drive earnings leverage over time, supported by a diversified commercial and pipeline portfolio.
Preliminary 2025 figures indicate
Management notes roughly
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of Principal Executive Offices)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. | Results of Operations and Financial Condition. |
The information set forth on pages 10-11 of the updated corporate presentation furnished under Item 7.01 of this Current Report on Form 8-K is incorporated herein by reference.
| Item 7.01. | Regulation FD Disclosure. |
On March 2, 2026, XOMA Royalty Corporation, a Nevada corporation (the “Company”), made available an updated corporate presentation, which is attached to this Current Report on Form 8-K as Exhibit 99.1.
The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit |
Description | |
| 99.1 | Corporate Presentation, dated March 2, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| XOMA ROYALTY CORPORATION | ||||||
| Date: March 2, 2026 | By: | /s/ Owen Hughes | ||||
| Name: | Owen Hughes | |||||
| Title: | Chief Executive Officer | |||||
Exhibit 99.1 CORPORATE PRESENTATION THE ROYALTY AGGREGATOR NASDAQ COMMON: XOMA FOR BIOTECH NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO COMPANIES Q1 2026
DISCLAIMERS Certain statements in this presentation are forward-looking statements 10-K and Form 10-Q. Consider such risks carefully when considering within the meaning of Section 27A of the Securities Act of 1933 and XOMA Royalty's prospects. Any forward-looking statements represent Section 21E of the Securities Exchange Act of 1934, including XOMA Royalty’s views only as of the date of this presentation and statements regarding: future potential monetization opportunities, should not be relied upon as representing its views as of any active transactions with significant financial implications, collaborations subsequent date. XOMA Royalty disclaims any obligation to update any poised for significant financial contribution, the ability of our partners forward-looking statement, except as required by law. and their licensees to successfully develop their pipeline programs, the productivity of acquired assets, our revenue and cashflow forecasts, NOTE: All references to “portfolio” in this presentation are to milestone upcoming internal milestones and value catalysts, our future cash and/or royalty rights associated with a basket of drug products in needs, our strategy for value creation, our future expenses and development. All references to “assets” in this presentation are to potential outcome of the ongoing litigation against Janssen, and other milestone and/or royalty rights associated with individual drug product statements that relate to future periods. These statements are not candidates in development. References to royalties or royalty rates guarantees of future performance and undue reliance should not be contained herein refer to future potential payment streams regardless placed on them. They are based on assumptions that may not prove of whether or not they are technically defined as royalties in the accurate, and actual results could differ materially from those underlying contractual agreement; further, any rates referenced herein anticipated due to certain risks inherent in the biotechnology industry are subject to potential future contractual adjustments. and for companies engaged in the development of new products in a regulated market. Potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty's most recent filings on Form 2
XOMA ROYALTY – WHAT WE DO Royalties Science Milestones Structuring The Biotech Royalty Aggregator 3
XOMA ROYALTY’S BUSINESS MODEL: Path to Sustained THE COMPOUNDING Profitability EFFECT GROWING # of ROYALTIES CASH RECEIPTS ↑ LOW EXPENSES LOW SHARE COUNT INFLECTION POINT HIGH EPS LOW EXPENSES SIGNIFICANT SHARE PRICE APPRECIATION 2023 future 4 4
XOMA ROYALTY IS DIFFERENTIATED Capital per transaction $ 200M+ Royalty Pharma $ 200M – $ 100M DRI Healthcare Trust FOCUSED ON $ Ligand HCRx 100M – EARLY- to MID-STAGE $ 25M CLINICAL ASSETS $ < 25M P R E C L I N I C A L P H A S E 1 P H A S E 2 P H A S E 3 A P P R O V A L C O M M E R C I A L 5
2025 YEAR IN REVIEW Increasing Portfolio Optionality Through Creative Deal Making Returning Excess Capital to Shareholders A P R 2 0 2 5 J U L 2 0 2 5 J A N 2 0 2 5 M A Y 2 0 2 5 Total 24 ADDED 1 O U T L I C E N S I N G R O Y A L T Y A C Q U I S I T I O N R O Y A L T Y + D-Fi Royalty, Warrants Sale of All Pipeline Assets ASSETS Mezagitamab Royalty Cash Phase 2 & 3 PRV 5 N A S D A Q : K N T E N A S D A Q : E P I X P R I V A T E N A S D A Q ( S W ) : B I N V ACQUIRED A U G 2 0 2 5 A U G 2 0 2 5 A U G 2 0 2 5 A U G 2 0 2 5 $ NON-DILUTIVE ~ 12M CAPITAL A C Q U I S I T I O N A C Q U I S I T I O N A C Q U I S I T I O N A C Q U I S I T I O N SEC 174 Benefits SEC 174 Benefits SEC 174 Benefits $ Dollars 16M SHARE N A S D A Q : M U R A N A S D A Q : L V T X N A S D A Q : T S B X N A S D A Q : H L V X BUYBACK D E C 2 0 2 5 N O V 2 0 2 5 D E C 2 0 2 5 Shares ~648k 1 R O Y A L T Y X - Δ A C Q U I S I T I O N A C Q U I S I T I O N SEC 174 TAX ctLNP Royalty Share Agreement Platform $ 2 DEDUCTIONS > 475M N Y S E : T A K N A S D A Q : R P R X N A S D A Q : G B I O 1. XOMA Royalty served as Structuring Agent and financing source to XenoTherapeutics, Inc. 6 2. Value includes estimated Section 174 tax deductions related to unamortized R&E
BUILDING THE LONG-TERM XOMA ROYALTY BUSINESS >100 Assets seralutinib (PAH/PH-ILD) (1L pLGG) ersodetug (HI) mezagitamab (ITP/IgAN) 1 volixibat (PBC/PSC) 2 $ osavampator (MDD) > 140M OHB-607 (BPD) milestones received since 2017 rilvegostomig (cancer) UNDISCLOSED Anti-TL1A (UC/Crohn’s) $ > 2B ficlatuzumab (HNSCC) in future potential cetrelimab (cancer) milestones ovaprene (NH Contraception) D-Fi (DEB) sildenafil cream (FSAD) MILESTONES EARLY-STAGE PIPELINE REGISTRATIONAL / PHASE 2b & 3 COMMERCIAL ROYALTIES 1. In development by Mirum Pharmaceuticals under license from Takeda. 7 2. Osavampator is being developed by Takeda in Japan, and by a Takeda partner outside of Japan.
COMMERCIAL PORTFOLIO Provide Stable & Growing Royalty Streams 3Q25YTD FY26 Peak Sales 1 1 Marketer Product Indication Royalties Receipts Sales Est Est Wet AMD, DME, $ $ $ 0.5% 22.5M 5.8B 8.3B RVO $ $ $ r/rpLGG Mid-single digit 8.5M 231M 910M Niemann-Pick $ $ $ Mid-single digit 2.0M 130M 392M Disease Type C $ $ Hemophilia-B Mid-single digit 1.3M 35M n/a Bacterial Low to high- $ < 0.5M n/a n/a Vaginosis single digit 37-75% on $ Acute Pain < 0.5M n/a n/a DoD sales 2 FSAD Low-single digit n/a n/a n/a 1. Consensus per Global Data or selected research analyst estimates if not available. AMD = Age-related Macular Degeneration, DME = Diabetic Macular Edema, RVO = Retinal Vein Occlusion, r/rpLGG = Relapsed or 8 2. Commercial availability through a 503B outsourcing facility. Progressive Pediatric Low-Grade Glioma, FSAD = Female Sexual Arousal Disorder, DoD = Department of Defense
+ B U S I N E S S D E V E L O P M E N T KEY PORTFOLIO EVENTS ANTICIPATED IN 2026 R E G U L A T O R Y C O M M E R C I A L M A R K E T I N G R E G U L A T O R Y G U I D A N C E : S A L E S R A M P S A U T H O R I Z A T I O N R E G I S T R A T I O N P A T H W A Y S D E C I S I O N S ( E M A , J a p a n ) S E R A L U T I N I B E R S O D E T U G R E C -4881 P U L M O N A R Y A R T E R I A L C O N G E N I T A L F A M I L I A L A D E N O M A T O U S H Y P E R T E N S I O N H Y P E R I N S U L I N I S M P O L Y P O S I S ( P A H ) ( c H I ) ( F A P ) ( E M A ) D A T A A N N O U N C E M E N T S PHASE 2b PHASE 3 PHASE 1 / 2 (Registrational) 1 P R O D U C T L A U N C H E R S O D E T U G V O L I X I B A T R I L V E G O S T O M I G H Y P E R I N S U L I N I S M P R I M A R Y S C L E R O S I N G L U N G C A N C E R ( m o n o t h e r a p y ) ( T H I ) C H L O A N G I T I S ( PSC ) 2H26 2Q26 2026 9 1. In development by Mirum Pharmaceuticals under license from Takeda.
XOMA ROYALTY SNAPSHOT: Current Capitalization $ 25.53 / SHARE SHARES (FULLY DILUTED 17.6M TREASURY METHOD) $ ~$ MARKET CAP (FULLY DILUTED) 449M 549M $ 69M PERPETUAL PREFERREDS ENTERPRISE VALUE $ 113M ROYALTY BACKED LOAN $ 82M CASH (YE25) 10 10 Note: Share Price as of market close 02/27/2026.
PRELIMINARY FY2025 FINANCIAL UPDATE 1 Item Amounts (unaudited ) $ FY2025 cash received from royalties and milestones ~ 49–50M $ 2 Cash, cash equivalents, and restricted cash as of December 31, 2025 ~ 133M Number of common shares repurchased and retired during FY 2025 648,048 $ Cash used to repurchase common stock during FY 2025 16.0M 3 Common shares outstanding as of February 27, 2026 11,888,489 Additional disclosure on unaudited G&A expenses G&A expenses for the year ended December 31, 2025 include an increase of approximately $1.0 million associated with ongoing litigation initiated by XOMA Royalty against Janssen Biotech, Inc. asserting claims for breach of contract and unjust enrichment arising from Janssen's unauthorized use of XOMA’s intellectual property in the commercialization of TREMFYA (guselkumab). XOMA Royalty expects to continue to incur legal fees and other professional service costs associated with pursuing this litigation. Litigation is inherently uncertain, and there can be no assurance regarding the outcome of the matter or the timing or amount of any potential recovery. 1. These amounts are preliminary and could change as a result of the Company completing its close process and finalizing the financial statements and related FY2025 audit. 2. Includes ~$82 million of unrestricted cash and cash equivalents and ~$51 million of restricted cash. 11 3. Excludes 5,003,000 common shares if converted from Series X Preferred Stock.
FAQ
What business model does XOMA (XOMA) highlight in its updated corporate presentation?
What preliminary FY2025 cash figures did XOMA (XOMA) disclose in the presentation?
How much XOMA (XOMA) stock was repurchased during FY2025 and at what cash cost?
What is XOMA’s (XOMA) common share count after the FY2025 buybacks?
How is ongoing litigation affecting XOMA’s (XOMA) 2025 expenses?
What does XOMA’s (XOMA) presentation say about potential future milestones?
Filing Exhibits & Attachments
5 documents